FDA-approved GLP-1 and GIP/GLP-1 brands; approval dates from Drugs@FDA, indications from current labels, both read November 8, 2026
BrandMoleculeRoute and scheduleLabel use (adults unless noted)First approved
Wegovy (pen, HD)SemaglutideInjection, weeklyWeight management (also ages 12+); CV risk reduction; MASH with fibrosisJune 2021
Wegovy pillSemaglutideTablet, dailyWeight management; CV risk reductionDecember 2025
OzempicSemaglutideInjection, weekly (tablets also sold)Type 2 diabetes; CV and kidney risk reduction in type 2 diabetesDecember 2017
RybelsusSemaglutideTablet, dailyType 2 diabetes; CV risk reduction in high-risk type 2 diabetesSeptember 2019
ZepboundTirzepatide (GIP and GLP-1)Injection, weeklyWeight management; moderate-to-severe sleep apnea with obesityNovember 2023
MounjaroTirzepatide (GIP and GLP-1)Injection, weeklyType 2 diabetes (also ages 10+); CV risk reduction in high-risk type 2 diabetesMay 2022
SaxendaLiraglutideInjection, dailyWeight management (also ages 12+ over 60 kg)December 2014
VictozaLiraglutideInjection, dailyType 2 diabetes (also ages 10+); CV risk reductionJanuary 2010
TrulicityDulaglutideInjection, weeklyType 2 diabetes (also ages 10+); CV risk reductionSeptember 2014
FoundayoOrforglipronTablet, dailyWeight managementApril 2026

Approval dates are each brand's original approval in Drugs@FDA, not the date a later indication was added. Zepbound's sleep apnea use, for example, came in December 2024, and Mounjaro's cardiovascular use appears in its current label, revised August 2026. Linked brands have full guides on this site; Victoza is covered on the liraglutide page, and Rybelsus and the Wegovy pill on the Ozempic and Wegovy pages.

Which GLP-1 medications are approved for weight loss?

Five brands in the table carry a weight-management label: Wegovy (pen and HD), the Wegovy pill, Zepbound, Saxenda and Foundayo. Each is approved for adults with obesity, or overweight plus at least one weight-related condition, alongside diet and activity changes.

The other five are diabetes medicines. Ozempic, Rybelsus, Mounjaro, Victoza and Trulicity are approved for type 2 diabetes, and most also carry a cardiovascular risk indication for people with diabetes. Weight change often appears in their trial results, but that is not the same as an approved weight use.

What is the difference between GLP-1 and GIP/GLP-1 drugs?

Semaglutide, liraglutide, dulaglutide and orforglipron act on one receptor, GLP-1. Tirzepatide acts on two, GIP and GLP-1, according to the Zepbound and Mounjaro labels.

GLP-1 is a natural hormone the labels describe as a regulator of appetite and calorie intake. The Zepbound label says nonclinical studies suggest adding GIP may contribute further, but it does not claim a mechanism proven in people. The only direct comparison of the two big weight drugs, SURMOUNT-5, found a mean 20.2% weight reduction with tirzepatide versus 13.7% with semaglutide at 72 weeks.

Pills or injections: which GLP-1s come by mouth?

Four products in the table are tablets: Rybelsus, Ozempic tablets, the Wegovy pill and Foundayo. All are taken once a day.

Saxenda and Victoza are daily injections. Wegovy, Ozempic, Zepbound, Mounjaro and Trulicity are weekly injections.

Do all GLP-1 medications carry the same warning?

Every one of the ten labels we read for this table carries a boxed warning about thyroid C-cell tumors seen in rodents, and each says the drug should not be used by people with a personal or family history of medullary thyroid carcinoma or with MEN 2. Stomach and bowel side effects such as nausea, diarrhea and vomiting are the most common across the class, and doses are increased slowly to reduce them.

Are there generic GLP-1 drugs?

Yes, for liraglutide. FDA approved the first generic referencing Victoza on December 23, 2024, and Drugs@FDA lists a Saxenda-referencing generic approved August 27, 2025, followed by more liraglutide approvals into 2026. As of November 8, 2026, Drugs@FDA showed no final approval of a generic semaglutide, tirzepatide or dulaglutide. It did show one tentative approval, dated April 7, 2026, for an Apotex semaglutide injection at the strengths of Ozempic's pens. A tentative approval means FDA found the application acceptable but the product cannot yet be marketed, usually because of patents or exclusivity.

Where do compounded GLP-1s fit?

Compounded semaglutide and compounded tirzepatide are not on the table because they are not FDA-approved. FDA's page on unapproved GLP-1 drugs, current as of October 1, 2026, says it does not review compounded drugs for safety, effectiveness or quality before sale. They are made with the drug in Wegovy or Zepbound, but they are not the same product.

Price is the main reason people consider them. Across the compounded programs in our price table, the lowest all-in monthly figure per program ran from $69 to $299 for tirzepatide (24 programs, median $149) and $39 to $249 for semaglutide (23 programs, median $99). Those reads are dated October 15, 2026, except NexLife's, dated November 6, 2026.

Two regulatory points matter. FDA proposed in April 2026 not to add tirzepatide, semaglutide or liraglutide to the 503B bulks list, and we found no final decision as of November 20, 2026. FDA also says some compounders use semaglutide salt forms, which it calls different active ingredients with no known lawful basis for compounding.

Frequently asked questions

How many GLP-1 drugs are approved for weight loss?

Among the brands on this page, five carry an FDA weight-management label as of November 8, 2026: Wegovy injection (including the 7.2 mg HD dose), the Wegovy pill, Zepbound, Saxenda and Foundayo. Ozempic, Rybelsus, Mounjaro, Victoza and Trulicity are approved for type 2 diabetes. Coverage and pricing usually follow the approved use, so the brand matters for payment.

What is Foundayo?

Foundayo is Lilly's brand of orforglipron, an oral GLP-1 receptor agonist that Drugs@FDA shows was approved on April 1, 2026 for weight management in adults with obesity, or overweight plus a weight-related condition. It is taken once daily with or without food. Doses start at 0.8 mg and can rise in 30-day steps to a maximum of 17.2 mg.

Is tirzepatide a GLP-1 drug?

Partly. Tirzepatide activates both the GIP receptor and the GLP-1 receptor, according to the Zepbound and Mounjaro labels, so it is often called a dual agonist rather than a pure GLP-1 drug. It is sold as Zepbound for weight management and sleep apnea and as Mounjaro for type 2 diabetes. Both are once-weekly injections from 2.5 mg to 15 mg.

Which GLP-1 medications are pills?

Four FDA-approved products are tablets: Rybelsus and Ozempic tablets for type 2 diabetes, and the Wegovy pill and Foundayo for weight management. The three semaglutide tablets must be taken on an empty stomach with a small amount of water. Foundayo, a different molecule, can be taken with or without food, per its label.

Is there a generic Wegovy or Ozempic?

Not as of our Drugs@FDA check on November 8, 2026. An Apotex semaglutide injection at Ozempic's pen strengths received only a tentative approval in April 2026, which does not allow sales. Liraglutide, the drug in Victoza and Saxenda, is the only GLP-1 with final generic approvals we found. Compounded semaglutide is not a generic and is not FDA-approved.

Sources

  1. Drugs@FDA (openFDA drugsfda endpoint): original approvals for Wegovy, Ozempic, Rybelsus, Zepbound, Mounjaro, Saxenda, Victoza, Trulicity, Foundayo — queried 2026-11-08 (e.g., Wegovy tablets NDA 218316 approved 2025-12-22; Foundayo NDA 220934 approved 2026-04-01)
  2. FDA labels (DailyMed) for all ten brands — indications sections read 2026-11-08; label versions: Wegovy 06/2026, Zepbound 08/2026, Mounjaro 08/2026, Ozempic SPL 06/2026, Rybelsus/Ozempic tablets 1/2026, Saxenda 02/2026, Victoza 05/2025, Trulicity SPL 06/2026, Foundayo SPL 07/2026
  3. FDA: FDA approves first generic of once-daily GLP-1 injection to lower blood sugar in patients with type 2 diabetes — press release December 23, 2024; read 2026-11-08
  4. FDA: FDA's concerns with unapproved GLP-1 drugs used for weight loss — content current as of 10/01/2026; read 2026-11-08
  5. FDA: FDA proposes to exclude semaglutide, tirzepatide and liraglutide from 503B bulks list — announced 2026-04-30 (91 FR 23431); status per facts file as of 2026-10-15
  6. Aronne LJ et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5). N Engl J Med 2025;393:26-36 — published July 3, 2025; abstract read 2026-11-08

Comparing programs? Check the all-in monthly price, the named pharmacy and the cancellation terms on the provider's own page before you pay.

Check NexLife's plans and state availability → See the price index

Researched By Dr. Parmis · Medical Researcher · Western University of Health Sciences

Medically Reviewed By Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)

Last medically reviewed: · This page is informational and does not constitute medical advice.